Elicio Therapeutics Inc
ELTX9.930USD
-0.050-0.50%
收盘 08/04, 16:00（美东）报价延迟15分钟
158.57M总市值
亏损市盈率 TTM
关于 Elicio Therapeutics Inc 公司
Elicio Therapeutics, Inc. 是一家临床阶段的生物技术公司。该公司致力于开发用于治疗癌症的免疫疗法。该公司提供了一个平台，即两亲物 (AMP)，可将免疫疗法直接输送到免疫系统的淋巴结（大脑中心）。该公司的主要候选产品 ELI-002 正在开发中，用于治疗由 kirsten 大鼠肉瘤 (KRAS) 引起的癌症。该公司正在进行 ELI-002 (AMPLIFY-201) 的 I/II 期临床试验。其 ELI-007 正在临床前研究中接受评估，用于治疗突变型 v-raf 鼠肉瘤病毒致癌基因同源物 B1 (BRAF) 引起的癌症，而 ELI-008 正在临床前研究中接受评估，用于治疗表达突变肿瘤蛋白 p53 (TP53) 的癌症。其AMP平台在治疗或预防癌症、传染病等疾病方面具有广阔的潜在应用前景。
公司简介
公司代码ELTX
公司名称Elicio Therapeutics Inc
上市日期Feb 05, 2021
CEOMr. Robert (Bob) Connelly
员工数量32
证券类型Ordinary Share
年结日Feb 05
公司地址451 D Street, 5Th Floor
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02459
电话18572090050
网址https://elicio.com/
公司代码ELTX
上市日期Feb 05, 2021
CEOMr. Robert (Bob) Connelly
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
GKCC, LLC
33.86%
Actyus Private Equity SGIIC, S.A.
5.35%
Knoll Capital Management, LLC
3.94%
Clal Biotechnology Industries Ltd
3.01%
The Vanguard Group, Inc.
2.01%
Other
51.82%
持股股东
持股股东
占比
GKCC, LLC
33.86%
Actyus Private Equity SGIIC, S.A.
5.35%
Knoll Capital Management, LLC
3.94%
Clal Biotechnology Industries Ltd
3.01%
The Vanguard Group, Inc.
2.01%
Other
51.82%
股东类型
持股股东
占比
Corporation
39.21%
Hedge Fund
5.54%
Investment Advisor
3.29%
Holding Company
3.01%
Individual Investor
1.65%
Investment Advisor/Hedge Fund
1.31%
Research Firm
0.33%
Bank and Trust
0.11%
Other
45.55%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
59
8.71M
54.45%
+612.65K
2025Q1
71
8.88M
57.84%
+3.95M
2024Q4
66
3.95M
32.81%
+187.04K
2024Q3
70
4.16M
40.61%
+80.64K
2024Q2
82
4.28M
44.94%
+434.22K
2024Q1
108
4.00M
44.25%
+126.75K
2023Q4
114
4.22M
52.86%
+1.57M
2023Q3
132
2.88M
52.57%
+376.65K
2023Q2
138
2.82M
63.05%
+1.05M
2023Q1
137
1.45M
48.19%
-243.12K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
GKCC, LLC
5.42M
33.86%
--
--
Jun 03, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.35%
+268.56K
+45.69%
Mar 31, 2025
Knoll Capital Management, LLC
630.91K
3.94%
--
--
Mar 31, 2025
Clal Biotechnology Industries Ltd
481.73K
3.01%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
321.69K
2.01%
+75.87K
+30.86%
Mar 31, 2025
Hudson Bay Capital Management LP
182.73K
1.14%
+182.73K
--
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.06%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
77.47K
0.48%
+6.75K
+9.54%
Mar 31, 2025
CM Management, LLC
55.00K
0.34%
+15.00K
+37.50%
Mar 31, 2025
Millennium Management LLC
52.22K
0.33%
+52.22K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
公告日期
类型
比率
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
